Search
EHA-RHS-ROHS Hematology Tutorial on Real World Challenges and Opportunities in Diagnostics and Management of Onco-hematological Patients Today
Dates: April 12-13, 2019
Location: Moscow, Russia
Chairs: P Sonneveld, I Poddubnaya, E Parovichnikova
Goal of the meeting
This 1,5 day meeting focuses on the most vital practical issues in oncohematology to teach the participants the appropriate and effective ways to use all the variety…
EHA: Bridging Breakthroughs in Hematology
The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready organization dedicated to addressing the needs of the European hematology community.
Read moreBleeding and Thrombosis
The objectives of the SWG on ‘Bleeding and Thrombosis’ are:
To promote education in the field of blood coagulation, including mechanisms, prevention, and treatment of bleeding and thrombotic disorders.
Highlights of Past EHA (HOPE) Latin America (LA) 2022 - report
November 17-19, 2022 – Barranquilla, Colombia
Meeting chairs:
D McLornan, Vice-Chair Global Outreach Program Committee, European Hematology Association (EHA)
V Abello Polo, President, Asociación Colombiana de Hematología y Oncología (ACHO)
This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana…
Recap: European Affairs and Hematology at EHA2024
As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.
Read moreGrants & abstract awards
EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET). New: Grant applications have been integrated into the EHA2025 Abstract Submission form.
Read moreMolecular Hematopoiesis Workshop
The Molecular Hematopoiesis Workshop at the EHA2025 Congress is back!
OrganizersChair: Michael Milsom (Germany)
Co-chairs: Kim De Keersmaecker (Belgium), Elisa Laurenti (United Kingdom) & Britta Will (United States)
Submit your abstract for the workshop here
Program The workshop will take place on Thursday, June…
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- »